Insider transactions
Elizabeth C. Cushman, who serves as Executive Vice President, General Counsel and Secretary at Abbott Laboratories (NYSE:ABT), executed two dispositions of company common stock in late February and early March 2026. On March 2, 2026, Cushman sold 263 shares at $115.58 per share, bringing the proceeds from that trade to $30,397. Earlier, on February 27, 2026, she disposed of 1,421 shares at $116.26 per share, generating $165,205; that February transaction was recorded as related to the satisfaction of tax obligations.
Following these sales, Cushman directly holds 38,573 shares of Abbott common stock.
Market context and valuation note
At the time of reporting the stock was trading at $113.61, which is below the levels at which Cushman sold the shares. Analysis provided through InvestingPro is cited as indicating the shares remain undervalued relative to Fair Value. For investors seeking further valuation detail, a Pro Research Report on ABT is noted as available exclusively on InvestingPro.
Corporate developments and financial signals
The company is described as a $197 billion healthcare firm that has maintained dividend payments for 56 consecutive years. Abbott declared a quarterly dividend of $0.63 per share in connection with its ongoing dividend program. Abbott also reported positive clinical results for its atrial fibrillation treatment systems, with studies showing an 84.2% success rate for paroxysmal AFib.
Strategic moves and earnings performance
Shareholders of Exact Sciences Corporation have, according to preliminary results, approved an acquisition by Abbott, with more than 99% of votes cast in favor based on preliminary tallies. Market responses to Abbott's recent financial performance have been mixed. The company's fourth-quarter results missed expectations, prompting Leerink Partners to lower its stock price target to $119, citing underperformance in several segments including Nutrition. Conversely, Freedom Capital Markets upgraded Abbott's rating to Buy, pointing to the Exact Sciences acquisition as a beneficial strategic step.
What this means
The transactions by a senior executive represent internal selling activity tied in part to tax obligations. Meanwhile, Abbott's combination of dividend continuity, clinical outcomes, a major acquisition vote and uneven quarterly results paints a complex picture for investors evaluating near-term operational execution against longer-term strategic moves.